Log In
BCIQ
Print this Print this
 

MolecularMD BCR-ABL T315I Mutation Test

  Manage Alerts
Collapse Summary General Information
Company MolecularMD Corp.
Descriptionin vitro diagnostic to to identify chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients who have the T315I mutation
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsIdentify chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients who have the T315I mutation
Regulatory Designation
PartnerAriad Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today